Novel insulin/igf/relaxin family polypeptides and dnas thereof
CA 2406855 A1 · Owner: Takeda Pharmaceutical Company Limited · Inventors: Itoh, Yasuaki; Harada, Masataka; Nishi, Kazunori
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
1) A polypeptide having an amino acid sequence being identical or substantially identical with the amino acid sequence represented by SEQ ID NO:7 (strand A); (2) a polypeptide having an amino acid sequence being identical or substantially identical with the amino acid sequence represented by SEQ ID NO:8 (strand B); (3) a polypeptide wherein the strand A and B are bonded to each other via a disulfide bond (double-stranded) or its salt; (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same are usable in, for example, diagnosing, treating and preventing diseases (diabetics, etc.) caused by metabolic errors of energy sources such as carbohydrates (for example, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 20, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 20, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 20, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.